- Trials with a EudraCT protocol (786)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (54)
786 result(s) found for: Infectious diseases.
Displaying page 1 of 40.
EudraCT Number: 2005-000567-25 | Sponsor Protocol Number: 100063 | Start Date*: 2005-08-10 | |||||||||||
Sponsor Name:NUMICO RESEARCH BV | |||||||||||||
Full Title: Tolerance and immunological response in HIV seropositive individuals after NR100063 supplementation | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004693-87 | Sponsor Protocol Number: 2004-04 | Start Date*: 2004-11-03 | |||||||||||
Sponsor Name:OSPEDALE SACRO CUORE-DON CALABRIA | |||||||||||||
Full Title: Randomized study on therapy of Strongyloides stercoralis invasion: ivermectine VS thiabendazole | |||||||||||||
Medical condition: Strongyloidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003986-42 | Sponsor Protocol Number: Rifa1 | Start Date*: 2008-06-18 | |||||||||||
Sponsor Name:University Hospital of Tübingen | |||||||||||||
Full Title: Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia | |||||||||||||
Medical condition: diarrhoea of travellers to South- and Southeast-Asia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024644-15 | Sponsor Protocol Number: 2010-024644-15 | Start Date*: 2012-02-07 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA' DEGLI STUDI DI NAPOLI | |||||||||||||
Full Title: Concomitant therapy with levofloxacyn versus sequential therapy with levofloxacin for eradication of H. pylori infection | |||||||||||||
Medical condition: Helicobacter pylori infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000938-19 | Sponsor Protocol Number: 4PH/2012/002 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:NOVINTETHICAL PHARMA SAGL | |||||||||||||
Full Title: Safety and Efficacy of tablets containing extract of Hibiscus Sabdariffa (HS) and Propoli versus placebo in the treatment of the cystitis with Ciproxin | |||||||||||||
Medical condition: patients with diagnosys of cystitis confirmed by urine culture | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002198-44 | Sponsor Protocol Number: P903-21 | Start Date*: 2011-07-22 | |||||||||||
Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | |||||||||||||
Full Title: Pharmacokinetics of a Single Dose of Ceftaroline fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection | |||||||||||||
Medical condition: Pharmacokinetics of a Single Dose of Ceftaroline fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed Infection | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004718-40 | Sponsor Protocol Number: MELCOM-1 | Start Date*: 2011-07-18 | |||||||||||
Sponsor Name:AISAR ASSOCIAZIONE ITALIANA PER LO STUDIO DEGLI ANTIMICROBICI E DELLE RESISTENZE | |||||||||||||
Full Title: Activities of Metronidazole + Clotrimazole in the treatment and prophylaxis of recurrent vaginal infections recurrent Candida albicans and Candida albicans spp do not. | |||||||||||||
Medical condition: women with vaginal infections by Candida albicans and non-albicans Candida spp relapsing recurrent (≥ 4 events / year) in the acute phase of the disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000610-20 | Sponsor Protocol Number: V70P4S | Start Date*: 2006-05-22 | |||||||||||
Sponsor Name:CHIRON | |||||||||||||
Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2006-2... | |||||||||||||
Medical condition: Active influenza immunoprofilaxis | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003281-25 | Sponsor Protocol Number: ALBIOS STUDY | Start Date*: 2008-04-17 | |||||||||||
Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS) | |||||||||||||
Full Title: Efficacy of albumin administration for volume replacement in patients with severe sepsis or septic shock | |||||||||||||
Medical condition: Patients with severe sepsis or septic shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000609-43 | Sponsor Protocol Number: V71P4S | Start Date*: 2006-05-22 | |||||||||||
Sponsor Name:CHIRON | |||||||||||||
Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of AGRIPPAL S1 Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, when Administer... | |||||||||||||
Medical condition: Active influenza immunoprofilaxis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005078-10 | Sponsor Protocol Number: FARM7X9F8K | Start Date*: 2008-10-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA VINCENZO MONALDI DI NAPOLI | |||||||||||||
Full Title: RANDOMISED, OPEN-LABEL CLINICAL TRIAL ON THE EFFICACY OF COLISTIN PLUS RIFAMPICIN TREATMENT VERSUS COLISTIN ALONE FOR SEVERE INFECTIONS BY MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII | |||||||||||||
Medical condition: Severe nosocomial infections due to multi-drug resistant Acinetobacter baumannii | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010586-23 | Sponsor Protocol Number: V70_09S | Start Date*: 2009-05-12 | |||||||||||
Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. | |||||||||||||
Full Title: A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, Adjuvanted with MF59C.1 Influenza Vaccine, Formulation 2009-201... | |||||||||||||
Medical condition: The virus strains responsible for influenza vary in an unpredictable fashion, therefore the type of virus as well as the magnitude of influenza activity changes from one winter to the other. Theref... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006132-24 | Sponsor Protocol Number: CDEB025A2313 | Start Date*: 2012-05-18 | |||||||||||
Sponsor Name:Novartis Farmaceutica, S.A. | |||||||||||||
Full Title: A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C p... | |||||||||||||
Medical condition: Chronic hepatitis C patients who failed to achieve sustained virologic response (SVR24) on alisporivir or direct-acting antivirals (DAA) in previous Novartis-sponsored studies. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Prematurely Ended) GB (Completed) PL (Prematurely Ended) IT (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005624-10 | Sponsor Protocol Number: OVID-trial | Start Date*: 2021-05-06 | ||||||||||||||||
Sponsor Name:University Hospital Zurich | ||||||||||||||||||
Full Title: ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL | ||||||||||||||||||
Medical condition: Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004586-13 | Sponsor Protocol Number: 117307 | Start Date*: 2014-04-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: Long-term hepatitis A and B antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-... | |||||||||||||
Medical condition: Healthy volunteers (Vaccination against hepatitis A and hepatitis B in healthy adults) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001433-74 | Sponsor Protocol Number: LOCAL/2017/CR-01 | Start Date*: 2017-06-29 | |||||||||||
Sponsor Name:CHU de NIMES | |||||||||||||
Full Title: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort | |||||||||||||
Medical condition: The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003470-47 | Sponsor Protocol Number: 74730.041.20 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:UMCU Utrecht [...] | |||||||||||||
Full Title: BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT SERIOUS RESPIRATORY TRACT INFECTION AND COVID-19 IN VULNERABLE ELDERLY – AN ADAPTIVE RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Protection Covid infection by patients with chronic diseases or major surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000173-22 | Sponsor Protocol Number: 2012-000173-22 | Start Date*: 2012-07-20 | ||||||||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | ||||||||||||||||||
Full Title: HEALTHCARE ASSOCIATED BACTERIAL INFECTIONS IN HOSPITALIZED CIRRHOTIC PATIENTS. RANDOMIZED TRIAL:EMPIRICAL TRADIDIONAL ANTIBIOTIC THERAPY VS SECOND LINE THERAPY | ||||||||||||||||||
Medical condition: Healthcare-associeted bacterial infections in hospitalized cirrhotic patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004035-88 | Sponsor Protocol Number: AntiCov | Start Date*: 2021-11-18 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotro... | |||||||||||||
Medical condition: Patients with mild to moderate SARS-COV-2 infection. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005884-29 | Sponsor Protocol Number: CRU-Unipg2020-12 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:UNIVERSITà DEGLI STUDI DI PERUGIA | |||||||||||||
Full Title: EFFICACY AND SAFETY OF HEPARIN THROMBOPROPHYLAXIS IN PATIENTS WITH COVID-19 AND RESPIRATORY FAILURE: AN OPEN LABEL RANDOMIZED STUDY. The RESPECT-COVID (RESPiratory failure and hEparin Clinical Tria... | |||||||||||||
Medical condition: Patients with confirmed SARS-CoV-2 infection and respiratory failure will be randomized to receive two different doses of low molecular weight heparin (LMWH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
